» Articles » PMID: 32825219

Identification of MicroRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Aug 23
PMID 32825219
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The underlying molecular mechanisms of the aberrant expression of components of the HLA class I antigen processing and presentation machinery (APM) in tumors leading to evasion from T cell-mediated immune surveillance could be due to posttranscriptional regulation mediated by microRNAs (miRs). So far, some miRs controlling the expression of different APM components have been identified. Using in silico analysis and an miR enrichment protocol in combination with small RNA sequencing, miR-26b-5p and miR-21-3p were postulated to target the 3' untranslated region (UTR) of the peptide transporter TAP1, which was confirmed by high free binding energy and dual luciferase reporter assays. Overexpression of miR-26b-5p and miR-21-3p in melanoma cells downregulated the TAP1 protein and reduced expression of HLA class I cell surface antigens, which could be reverted by miR inhibitors. Moreover, miR-26b-5p overexpression induced a decreased T cell recognition. Furthermore, an inverse expression of miR-26b-5p and miR-21-3p with TAP1 was found in primary melanoma lesions, which was linked with the frequency of CD8 T cell infiltration. Thus, miR-26-5p and miR-21-3p are involved in the HLA class I-mediated immune escape and might be used as biomarkers or therapeutic targets for HLA class I melanoma cells.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.


Exploring prognostic DNA methylation genes in bladder cancer: a comprehensive analysis.

Zhang J, Chen J, Xu M, Zhu T Discov Oncol. 2024; 15(1):331.

PMID: 39095590 PMC: 11297003. DOI: 10.1007/s12672-024-01206-7.


Identification of RNA-binding protein hnRNP C targeting the 3'UTR of the TAP-associated glycoprotein tapasin in melanoma.

Wang Y, Seliger B Oncoimmunology. 2024; 13(1):2370928.

PMID: 38948930 PMC: 11212565. DOI: 10.1080/2162402X.2024.2370928.


Strategies to overcome low MHC-I expression in paediatric and adult tumours.

Guillaume J, Perzolli A, Boes M Immunother Adv. 2024; 4(1):ltad028.

PMID: 38223409 PMC: 10787372. DOI: 10.1093/immadv/ltad028.


Lymphocyte to monocyte ratio predicts survival and is epigenetically linked to miR-222-3p and miR-26b-5p in diffuse large B cell lymphoma.

Metwally A, Kasem A, Youssif M, Hassan S, Abdel Wahab A, Refaat L Sci Rep. 2023; 13(1):4899.

PMID: 36966176 PMC: 10039925. DOI: 10.1038/s41598-023-31700-x.


References
1.
Seliger B, Ferrone S . HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. Methods Mol Biol. 2019; 2055:325-350. DOI: 10.1007/978-1-4939-9773-2_15. View

2.
Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

3.
Koelblinger P, Emberger M, Drach M, Cheng P, Lang R, Levesque M . Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. J Eur Acad Dermatol Venereol. 2018; 33(4):667-675. DOI: 10.1111/jdv.15302. View

4.
Nana-Sinkam S, Croce C . MicroRNA regulation of tumorigenesis, cancer progression and interpatient heterogeneity: towards clinical use. Genome Biol. 2014; 15(9):445. PMC: 4709998. DOI: 10.1186/s13059-014-0445-8. View

5.
Gao Q, Liang W, Foltz S, Mutharasu G, Jayasinghe R, Cao S . Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018; 23(1):227-238.e3. PMC: 5916809. DOI: 10.1016/j.celrep.2018.03.050. View